2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120611
    BMS-960 free base 1265321-86-5 98%
    BMS-960 free base is a potent and selective S1P1 receptor agonist containing isoxazole, which can be used in the research of immune diseases and vascular diseases.
    BMS-960 free base
  • HY-120612
    BMS-884775 1557206-59-3 98%
    BMS-884775 is a selective and orally active P2Y1 antagonist with an IC50 of 0.1 nM for the human P2Y1 receptor. BMS-884775 has a similar efficacy in preventing arterial thrombosis to Clopidogrel (HY-15283) and Prasugrel (HY-15284), but treatment with BMS-884775 results in shorter bleeding time and lower bleeding risk. BMS-884775 can be used in research related to antiplatelet and arterial thrombosis-associated diseases.
    BMS-884775
  • HY-120648
    CAY 10434 769917-29-5 98%
    CAY 10434 is a potent CYP4A hydroxylase inhibitor. CAY 10434 improves contractile response to angiotensin II with the maximal contractile response (Emax) 6764 mg.
    CAY 10434
  • HY-120673
    SQ 32970 122280-12-0 98%
    SQ 32970 is a tripeptidic renin inhibitor. SQ 32970 potently inhibits endothia protease.
    SQ 32970
  • HY-120694
    ML165 1355454-05-5 98%
    ML165 (RUC-2) is an aIIbb3 receptor antagonist. ML165 has orthosteric inhibition effect at the RGD binding domain. ML165 inhibits platelet adhesion to fibrinogen, and inhibits platelet aggregation (IC50: 96 nM).
    ML165
  • HY-120718
    CCG 224061 2055990-82-2 98%
    CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes. CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension.
    CCG 224061
  • HY-120730
    DA 1686 13071-27-7 98%
    DA 1686 is a potent and orally active anti-arrhythmic agent.
    DA 1686
  • HY-120774
    GS-462808 1354198-41-6 98%
    GS-462808 is an oral active late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with the IC50 of 1.33 μM. GS-462808 can be used for study of arrhythmia.
    GS-462808
  • HY-120776
    SC-51316 133690-62-7 98%
    SC-51316 is an oral active angiotensin II receptor antagonist with the IC50 values of 3.6 and 5.1 nM in rat adrenal cortical and rat uterine membrane, respectively. SC-51316 shows antihypertensive activity in vivo and in vitro.
    SC-51316
  • HY-120816
    WU-07047 1702378-78-6 98%
    WU-07047, a simplified analog of YM-254890 (HY-111557), is a selective Gαq/11 inhibitor. WU-07047 can inhibit nucleotide exchange.
    WU-07047
  • HY-120818
    TRPC3/6-IN-3 1366234-01-6 98%
    TRPC3/6-IN-3 is a selective TRPC3/6 blocker. TRPC3/6-IN-3 can be used for the research of cardiovascular disease.
    TRPC3/6-IN-3
  • HY-120829
    Bisoprolol fumarate 105878-43-1 98%
    Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol fumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
    Bisoprolol fumarate
  • HY-120917
    BRD1172 1597438-86-2 98%
    BRD1172 (ML320) is a selectivity GSK3β inhibitor with an IC50 of 24 nM for GSK3β over CDK5. BRD1172 significantly inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells, and relieves negative regulation by GSK3β on β-catenin degradation and TCF/LEF promoter activities. BRD1172 can be used for Alzheimer’s disease, cardiac hypertrophy and cancers research.
    BRD1172
  • HY-120941
    LASSBio-1359 1396397-19-5 98%
    LASSBio-1359 is an adenosine A2A receptor agonist with vasodilatory and anti-inflammatory activities.
    LASSBio-1359
  • HY-12096A
    WAY-207024 dihydrochloride 872002-73-8 98%
    WAY-207024 dihydrochloride is an orally active gonadotropin releasing hormone receptor (GnRH-R) antagonist (human GnRH: IC50 of 12 nM, rat GnRH: IC50 of 71 nM). WAY-207024 dihydrochloride inhibits rat LH release with an IC50 of 350 nM. WAY-207024 dihydrochloride lowers rat plasma leuteinizing hormone (LH) levels after oral administration.
    WAY-207024 dihydrochloride
  • HY-120997
    E6 Berbamine 114784-59-7 98%
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia.
    E6 Berbamine
  • HY-121183
    Aprikalim 132562-26-6 98%
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions.
    Aprikalim
  • HY-121215
    Chloracyzine 800-22-6 98%
    Chloracyzine is an antianginal agent with spasmolytic properties and prevent or relieve spasms of the coronary vessels. Chloracyzine shows a moderate antihistaminic effect.
    Chloracyzine
  • HY-121232
    Delapril 83435-66-9 98%
    Delapril (CV-3317) is an orally active angiotensin I converting enzyme (ACE) inhibitor. Delapril has antihypertensive activity.
    Delapril
  • HY-121259
    Doxorubicinol 54193-28-1 98%
    Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
    Doxorubicinol
Cat. No. Product Name / Synonyms Application Reactivity